Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Uterine Cervical Neoplasms 2Kidney Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thymoma 1Solid Tumor 1Rectal Neoplasms 1Oligometastatic Prostate Cancer 1Neoplasms 1Metastatic Urothelial Cancer 1Lung Neoplasms 1Lung Diseases 1Locally Advanced Cervical Cancer 1Gestational Trophoblastic Disease 1Gastro-enteropancreatic neuroendocrine tumor 1Erythrocytosis, Familial, 4 1Cholangiocarcinoma 1Carcinoid Tumor 1Breast Neoplasms 1Bile Duct Neoplasms 1Advanced Solid Tumors 1Advanced Solid Tumor 1

Interventions

pembrolizumab 38Blood Specimen Collection 38Bevacizumab 22Surveys and Questionnaires 18Standard of Care 18Radiotherapy 17Exercise 17Carboplatin 17Nivolumab 15atezolizumab 14Paclitaxel 14Cisplatin 14Drug Therapy 13Fluorouracil 12Cyclophosphamide 12Cetuximab 11Trastuzumab 10Pemetrexed 10Leucovorin 10Docetaxel 10Dexamethasone 10Oxaliplatin 9Biopsy 9pertuzumab 8olaparib 8Temozolomide 8Panitumumab 8Observation 8Irinotecan 8abemaciclib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neoplasms × zimberelimab × Clear all
NCT06759649 2026-02-27

A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies

Compugen Ltd

Phase 1 Recruiting
200 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡